undamentalytics Newsletter
Sign in

Lifemd, Inc. income statement

In fiscal 2025, Lifemd, Inc. reported revenue of $194m, up 25.3% on the year before, operating income of −$7.7m (a -4.0% margin) and net income of $14.4m, or $0.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1111548123793119153155194165
Cost of revenue000021239181919212823
Gross profit0111336102875100134133166142
Research and development———0———————————
Selling and marketing——————5939837876708686
General and administrative0000112245404752585852
Operating income−1−1−1−0−1−1−2−3−58−54−43−14−20−8−24
Interest expense00000001231321−0
Income before tax−0−0−0−0−1−1−2−4−60−61−45−17−23−10−25
Income tax——————−0−0000010—
Net income−0−0−0−0−1−1−1−3−59−61−46−21−21140
Diluted EPS−$0.01−$0.01−$0.01$0.00−$0.01−$0.01——————−$0.60$0.25$0.00
Diluted shares (average)11m12m12m12m13m17m18m20m29m27m31m34m41m45m47m
EBITDA−0−0−0−0—————−54−43−14−20−7−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CCLD vs LFMDAMWL vs LFMDDH vs LFMD

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Lifemd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lifemd, Inc.